Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schneider, Miklos
NCT06124677: Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments	Completed	N/A	46	Europe	Faricimab, Vabysmo (6 mg, 0.05 ml)	Rigshospitalet, Denmark	Neovascular Age-related Macular Degeneration	11/23	12/23
NCT06231121: Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab	Completed	N/A	13	Europe	Faricimab, Vabysmo (6 mg, 0.05 ml)	Rigshospitalet, Denmark	Neovascular Age-related Macular Degeneration	01/24	01/24